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Summary
 
Complement is part of the innate immune system and one of the first lines of host defense
against infections. Its importance was evaluated in this study in virus infections in mice defi-
cient either in soluble complement factors (C3
 
2
 
/
 
2
 
, C4
 
2
 
/
 
2
 
) or in the complement signaling
complex (complement receptor [CR]2
 
2
 
/
 
2
 
, CD19
 
2
 
/
 
2
 
). The induction of the initial T cell–inde-
pendent neutralizing immunoglobulin (Ig)M antibody response to vesicular stomatitis virus
(VSV), poliomyelitis virus, and recombinant vaccinia virus depended on efficient antigen trap-
ping by CR3 and -4–expressing macrophages of the splenic marginal zone. Neutralizing IgM
and IgG antibody responses were largely independent of CR2-mediated stimulation of B cells
when mice were infected with live virus. In contrast, immunizations with nonreplicating anti-
gens revealed an important role of B cell stimulation via CR2 in the switch to IgG. The com-
plement cascade was activated after infection with VSV via the classical pathway, and active
complement cleavage products augmented the effector function of neutralizing IgM and IgG
antibodies to VSV by a factor of 10–100. Absence of the early neutralizing antibody responses,
together with the reduced efficiency of neutralizing IgM in C3
 
2
 
/
 
2
 
 mice, led to a drastically en-
hanced susceptibility to disease after infection with VSV.
Thus, complement enhances the immunogenicity of various viruses mainly by promoting
antigen trapping to CR-expressing macrophages in the marginal zones of secondary lymphoid
organs, a process that leads to activation of B cells independent of T cell help; therefore, the T
cell–independent activation of virus-neutralizing epitope–specific B cells is largely dependent
on complement.
Key words: complement • CD19 • antiviral immunity • T cell independence • neutralizing 
antibodies
 
T
 
he importance of complement in protection against
bacterial infection has been extensively documented;
complement deficiencies are often associated with bacterial
infections (1, 2). Different possibilities of virus interacting
with the complement system have been described in vitro
(3, 4), and complement components have been shown to
enhance the specific antibody response to different model
antigens (5–8). These results indicate an important link be-
tween innate and acquired immunity (9, 10). In viral infec-
tions, C3 and C4 may directly coat a virion and thereby
prevent infection of target cells or lead to direct lysis of the
virus (11). In addition, complement components can bind
and lyse virus-infected cells (12). Several viruses have
evolved strategies to evade complement lysis either by us-
ing complement receptors (CRs)
 
1
 
 and complement control
proteins as viral receptors or by producing complement-
blocking or -modulating molecules (3, 13).
In various experimental systems using mAbs to comple-
ment components or soluble CRs, impaired immune re-
sponses to T cell–dependent (TD) antigens have been de-
scribed (14–17). More recently, immunization of mice
deficient in soluble complement components or in CRs
 
1
 
Abbreviations used in this paper:
 
 AFC, antibody-forming cell; CRs, com-
plement receptors; FDCs, follicular dendritic cells; G, glycoprotein; GC,
germinal center; L, ligand; LCMV, lymphocytic choriomeningitis virus;
NP, nucleoprotein; RT, room temperature; TD, T cell–dependent; TI,
T cell–independent; VSV, vesicular stomatitis virus. 
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with low doses of different model antigens have confirmed
these observations (1, 18–20). For example, C3d coupled
to hen egg lysozyme (HEL) is 1,000–10,000-fold more im-
munogenic than HEL alone (21). Two mechanisms to ex-
plain the increase in immunogenicity have been proposed.
First, opsonization of the antigen by complement enhances
the targeting of antigen to follicular dendritic cells (FDCs),
which express CD35 (CR1) and CD21 (CR2), leading to
more efficient antigen presentation to B cells and germinal
center (GC) formation (22, 23). Second, a direct enhancement
of B cell receptor signal transduction has been proposed, a
concept called “dual antigen recognition” (6, 8): CR2 is ex-
pressed on B cells and forms a complex with CD19 and
TAPA-1 (target of antiproliferative antibody 1); however,
CR2 does not possess an intracellular domain and therefore,
after binding of C3b and C3d, CR2 probably signals via
CD19. As a consequence, active cleavage products of C3
bound to antigen induce the cross-linking of the B cell recep-
tor with the coreceptor complex and lower the threshold for
B cell activation. Mice deficient in soluble complement com-
ponents or in CR1 and CR2 are able to initiate GC formation
after immunization, but these GCs are reduced in number and
size (18, 19). Antigen concentration on FDCs is drastically re-
duced in CD21/CD35-deficient mice. In addition, as CD21–
CD21L (ligand) interaction has been shown to provide signals
for GC B cells to become memory B cells (24), a reduction in
antigen persistence on FDCs and a decrease in GC B cell sur-
vival may influence long-term B cell memory, although this
has not yet been formally demonstrated.
The role of complement components in the initiation of
a protective neutralizing antibody response to viral infec-
tions in vivo has remained largely unexplored. We there-
fore studied the interaction of various cytopathic and non-
cytopathic viruses with the complement system using the
recently generated mice deficient in the central comple-
ment component of both activation pathways (C3
 
2
 
/
 
2
 
; ref-
erence 1), deficient in a component of the classical pathway
(C4
 
2
 
/
 
2
 
; reference 20), or with defects in the receptor sig-
naling complex (CD19
 
2
 
/
 
2
 
, reference 25; CR2
 
2
 
/
 
2
 
, refer-
ence 18). It is noteworthy that murine CR1 and CR2 are
alternative transcripts of the CR2 gene. Therefore, inacti-
vation of the CR2 gene in CR2
 
2
 
/
 
2
 
 mice led to a defi-
ciency in both CR1 and CR2 (18).
Many bacteria and viruses activate B cells independent of
Th cells. They can be divided into two groups (26): T cell–
independent type 1 (TI-1) antigens activate B cells without
the need of second signals, either in a polyclonal (prototype
LPS) or antigen-specific fashion (several viruses such as ve-
sicular stomatitis virus [VSV]; reference 27); in contrast,
TI-2 antigens need residual noncognate T cell help for ac-
tivation of B cells (i.e., bacterial polysaccharides, poliomy-
elitis virus, recombinant vaccinia virus). We analyzed infec-
tion of mice with VSV, a close relative of rabies virus and a
member of the 
 
Rhabdoviridae
 
 (28, 29). VSV is in mice a
largely neurotropic, highly cytopathic virus that causes pa-
ralysis and death if it reaches neuronal tissues (28, 30). Re-
covery from primary infection and resistance against re-
infection depends virtually exclusively on neutralizing
antibodies and not on cytotoxic T cells (31). As for infec-
tions with many cytopathic viruses (e.g., polio, influenza,
and rhabdoviruses), recovery from infection is crucially de-
termined by initial distribution of the virus after systemic
spread and early protective defense mechanisms during the
first few hours after infection (28).
 
Materials and Methods
 
Mice.
 
The generation of C3
 
2
 
/
 
2
 
, C4
 
2
 
/
 
2
 
, CR2
 
2
 
/
 
2
 
, and
CD19
 
2
 
/
 
2
 
 mice has been described previously (1, 18, 20, 25).
C57BL/6 and 129Sv mice were purchased from the Institute for
Laboratory Animals (Veterinary Hospital, Zurich, Switzerland).
C57BL/6 and (C57BL/6 
 
3
 
 129Sv)F1 were used as controls. Ex-
periments were done in a conventional mouse house facility, and
mice were used at 6–12 wk of age.
 
Virus and Measurement of VSV Titers.
 
VSV Indiana (VSV-
IND; Mudd-Summers isolate) and VSV New Jersey (VSV-NJ;
Pringle isolate) were originally received from Dr. D. Kolakovsky
(University of Geneva, Switzerland) and were grown on BHK21
cells. Lymphocytic choriomeningitis virus (LCMV)-WE was
originally obtained from Dr. F. Lehmann Grube (Heinrich Pette
Institute, Hamburg, Germany) and was propagated on L929 fi-
broblast cells. Poliovirus stock solutions of serotype II were ob-
tained from the Swiss Serum and Vaccine Institute (Bern, Swit-
zerland). Inactivated poliovirus vaccine containing all three major
serotypes (Salk) was purchased from BERNA, Switzerland. Re-
combinant baculoviruses expressing the glycoprotein of VSV
(VSV G) and the nucleoprotein of LCMV (LCMV NP) were
gifts from Dr. D.H.L. Bishop (NERC Institute of Virology, Ox-
ford, UK). They were derived from nuclear polyhedrosis virus
and were grown at 28
 
8
 
C in 
 
Spodoptera frugiperda
 
 cells in spinner
cultures (32).
VSV titers in different organs were analyzed by a plaque-form-
ing assay. 1:10 serial dilutions of organ homogenates were incu-
bated on a vero cell monolayer in 24-well plates for 1 h at 37
 
8
 
C
in an atmosphere with 5% CO
 
2
 
. Overlay with methylcellulose,
incubation, and staining of plaques was similarly done as de-
scribed for the neutralization assay.
 
VSV and Poliomyelitis Virus Neutralization Assay.
 
Serum of
immunized mice was prediluted 40-fold in MEM containing 2%
FCS. Serial twofold dilutions were mixed with equal volumes of
VSV (500 pfu/ml) and incubated for 90 min at 37
 
8
 
C in an atmo-
sphere with 5% CO
 
2
 
. 100 
 
m
 
l of the serum–virus mixture was
transferred onto vero cell monolayers in 96-well plates and incu-
bated for 1 h at 37
 
8
 
C. The monolayers were overlaid with 100 
 
m
 
l
DMEM containing 1% methylcellulose and incubated for 24 h at
37
 
8
 
C. The overlay was flicked off, and the monolayer was fixed
and stained with 0.5% crystal violet. The highest dilution of se-
rum that reduced the number of plaques by 50% was taken as ti-
ter. To determine IgG titers, undiluted serum was pretreated
with an equal volume of 0.1 mM 
 
b
 
-ME in saline. Poliovirus
neutralization assays were performed similarly, but samples were
prediluted 1:20.
 
LCMV NP–specific ELISA.
 
We used an ELISA with the fol-
lowing steps: (a) coating with baculovirus-derived LCMV NP (1
 
m
 
g/ml); (b) blocking with 2% BSA (Fluka AG) in PBS; (c) addi-
tion of 10-fold–prediluted sera, titrated 1:3 over 12 dilution steps;
(d) detection with IgM- or IgG-specific horseradish peroxidase–
labeled goat anti–mouse antibodies (0.5 
 
m
 
g/ml; Southern Bio-
technology Associates, Inc.); and (e) addition of substrate ABTS
(2.2
 
9
 
-azino-bis-[3-ethylbenzthiazoline-6-sulfonate]; Boehringer 
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Mannheim) and H
 
2
 
O
 
2
 
 (Fluka AG). Plates were coated overnight
at 4
 
8
 
C; all other incubations were done for 60–90 min at room
temperature (RT). Between incubations, plates were washed
three times with PBS containing 0.05% Tween-20. OD was
measured at 405 nm in an ELISA reader, and antibody titers were
determined as the serum dilutions yielding an absorption of twice
background levels.
 
Enzyme-linked Immunospot Assay for VSV-specific Antibody-form-
ing Cells.
 
Antibody-forming cell (AFC) frequencies were deter-
mined as described (33). In brief, 25 square-well polystyrene
plates were coated with purified VSV-IND (
 
<
 
10
 
11
 
 pfu/ml). On
the next day, plates were blocked with 2% BSA in PBS for 2 h.
Titrated amounts of single-cell suspensions were added in 2%
MEM and incubated for 5 h at 37
 
8
 
C. After washing with PBS–
Tween, goat anti–mouse IgM or IgG antibody (2 
 
m
 
l/ml; EY
Labs.) was added, and plates were incubated for 2 h at 37
 
8
 
C. Af-
ter washing with PBS–Tween, alkaline phosphatase–labeled don-
key anti–goat antibody (1 
 
m
 
g/ml; Jackson ImmunoResearch
Labs, Inc.) was added, and plates were incubated overnight at
RT. The next day, plates were washed, and the substrate solution
(5-bromo-4-chloro-3-indolyl phosphate at 1 
 
m
 
g/ml in 0.6% aga-
rose) was added to develop blue color spots.
 
In Vivo CD4
 
1
 
 T Cell Depletion.
 
Mice were treated intraperi-
toneally on days 3 and 1 before infection with 1 mg of anti-CD4
mAb YTS191.1 (34). This treatment completely abrogates the
switch from IgM to IgG and depletes CD4
 
1
 
 T helper cells to be-
low detection level by FACS™ analysis (not shown).
 
Immunohistochemistry.
 
Freshly removed organs were im-
mersed in HBSS and snap frozen in liquid nitrogen. 5-
 
m
 
m-thick
tissue sections were cut in a cryostat, placed on siliconized glass
slides, air dried, fixed with acetone for 10 min, and stored at
 
2
 
70
 
8
 
C. For staining of cell differentiation markers, rehydrated
sections were incubated with rat mAbs against marginal zone
macrophages (ERTR-9; reference 35) and against marginal zone
metallophils (MOMA-1; Biomedicals). Primary rat antibodies
were revealed by sequential incubation with goat antibodies to
rat Igs (Caltag Labs.) and alkaline phosphatase–labeled donkey
antibodies to goat Igs (Jackson ImmunoResearch Labs., Inc.). Di-
lutions of secondary antibodies were made in TBS containing 5%
normal mouse serum. Incubations were done at RT for 30 min;
TBS was used for all washing steps. Alkaline phosphatase was vi-
sualized using naphthol AS-BI (6-bromo-2-hydroxy-3-naph-
tholic acid-2-methoxy anilide) phosphate and new fuchsin as
substrate. Endogenous alkaline phosphatase was blocked by
levamisole. Color reactions were performed at RT for 15 min
with reagents from Sigma Chemical Co. Sections were counter-
stained with hemalum, and coverslips were mounted with glyc-
erol and gelatin. Staining for VSV antigen was done as described
(36).
 
Results
 
A Role for Complement in IgG Antibody Responses against
Nonreplicating Viral Antigens but Not against Replicating Virus.
 
Primary neutralizing antibody responses against VSV or
recombinant VSV G protein and ELISA binding anti-
bodies against LCMV NP were assayed (Fig. 1) in C3
 
2
 
/
 
2
 
and control mice. The early (day 2–6) IgM response to
VSV was completely TI-1; thereafter, VSV induced a rapid
and strong TD neutralizing IgG response starting around
day 6–7 after infection, reaching a plateau level after 3 wk
(31). VSV G on the membranes of cells infected with a re-
combinant vaccinia virus expressing VSV G (Vacc VSV G)
and baculovirus-expressing VSV G protein have been
shown to be TI-2 antigens (27). In contrast, IgM and IgG
antibodies to LCMV NP (an internal viral antigen) are
strictly dependent on Th cells.
After infection with the two replicating viruses express-
ing the VSV G as TI antigen (VSV, 2 
 
3
 
 10
 
6
 
 pfu i.v., Fig. 1
A; and Vacc VSV G, 2 
 
3
 
 10
 
6
 
 pfu i.v., Fig. 1 C), a compa-
Figure 1. Antibody responses to replicating and nonreplicating TI-1,
TI-2, and TD viral antigens. C32/2 (j, d) and control mice (h, s)
([C57BL/6 3 129Sv]F1 or C57BL/6) were immunized with (A) 2 3 106
pfu live VSV i.v., (B) 2 3 108 pfu VSV UV-inactivated i.v., (C) 2 3 106
pfu Vacc VSV G, or (D) 10 mg baculovirus VSV G protein i.v. Neutraliz-
ing antibody titers were assessed at the time points indicated. In the ex-
periment shown, three out of five C32/2 mice died between day 8 and 12
after infection with VSV (Table I). Antibody titers in the dying mice
were not different from those in surviving mice. After immunization with
(E) 200 pfu LCMV-WE or (F) UV-inactivated purified LCMV-WE
(z20 mg protein), LCMV NP–specific antibodies were determined in an
ELISA on baculovirus-derived LCMV NP–coated plates. Titers are
shown as dilutions leading to OD 405 nm twice over background. (G)
C32/2 and control mice were immunized every other day until day 12
with 2 3 108 pfu UV-inactivated VSV, and neutralizing antibody titers
were measured. (H) CR22/2 and control mice were immunized once
with 2 3 108 pfu UV-inactivated VSV, and VSV-IND–neutralizing anti-
body titers were assessed at the time points indicated. All results (A–H)
are given as mean 6 SD of three mice per group. Experiments were re-
peated twice with similar results. 
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rable antibody response was observed in wild-type and
C3
 
2
 
/
 
2
 
 mice; the initial TI IgM response was, surprisingly,
somewhat delayed in C3
 
2
 
/
 
2
 
 mice, whereas the TD switch
to IgG was comparable in C3
 
2
 
/
 
2
 
 and control mice. In con-
trast, after immunization with nonreplicating viral antigens
(2 
 
3
 
 10
 
8
 
 pfu i.v. UV-inactivated VSV, Fig. 1 B; and 10 
 
m
 
g
i.v. baculovirus-derived VSV G protein, Fig. 1 D), a reduc-
tion in the TD IgG antibody responses by a factor of 
 
z
 
8
against inactivated VSV and a factor of 
 
z
 
60–100 against
VSV G protein was observed. It has been shown previously
that for immunization with nonreplicating antigens, higher
amounts of antigen had to be used to induce an antibody
response comparable to that after infection with 2 
 
3
 
 10
 
6
pfu live VSV (37). In this study, we used 2 3 108 pfu
equivalents of UV-inactivated VSV (100 times more than
live VSV, Fig. 1 B) and 10 mg baculovirus-derived VSV G
protein (corresponding to z105 times more VSV G protein
than expressed on 2 3 106 pfu of live VSV, Fig. 1 D). This
comparison was based on virus particles counted by elec-
tron microscopy and on one virus particle expressing
z1,300 VSV G proteins in its envelope (29). With a high
initial antigen dose, the early IgM response could be re-
stored in C32/2 mice (Fig. 1, B and D). Interestingly, the
capacity of C32/2 mice to mount TD IgM and IgG anti-
bodies against LCMV NP after infection with 200 pfu
LCMV i.v. was similar to that of controls (Fig. 1 E). Im-
munization with UV-inactivated LCMV subcutaneously
(300  ml of purified LCMV in CFA corresponding to z20
mg of protein) also revealed an z10-fold reduction of the
IgG titer (Fig. 1 F).
The reduced IgG titers after immunization with non-
replicating viral antigens confirm earlier results with model
TD antigens (bacteriophage FX174, sheep red blood cells) in
C32/2 and CR22/2 mice (1, 18, 19). In contrast, during
infections with live virus, where efficient T cell help and/
or antigen persistence is provided (Fig. 1, A, C, and E),
switching to IgG is here shown to be largely complement
independent. The influence of antigen dose and antigen
persistence in vivo on the antibody response was analyzed
in C32/2 and control mice that were immunized repeti-
tively every other day with 2 3 108 pfu UV-inactivated
VSV (Fig. 1 G). Repetitive injections of high doses of
nonreplicating VSV particles induced comparable IgG ti-
ters in C32/2 and control mice. This indicates, first, that B
cells of C32/2 mice are comparably functional in vivo and
second, that the influence of complement on the specific
immune response probably reflects the importance of anti-
gen dose and persistence. The reduced IgG titers in C32/2
mice may be a consequence of an impaired interaction
of antigen-bound complement cleavage products with
CD21/CD35. To test this hypothesis, the immune re-
sponse of CR22/2 mice to viral antigens was analyzed
(Fig. 1 H). The blocked switch to IgG in CR22/2 mice
after immunization with 2 3 108 pfu UV-inactivated VSV
confirms the importance of the CD21–CD21L interaction
in the enhancement of B cell stimulation and/or antigen
trapping on FDCs in response to nonreplicating antigen.
In contrast, the IgG response after infection with live vi-
ruses in C32/2 (Fig. 1, A, C, and E) and CR22/2 (not
shown) was within normal ranges.
Increased Susceptibility of C32/2 Mice to Paralytic Disease af-
ter Infection with VSV. Recovery of mice from primary or
secondary VSV infection depends mainly on the neutraliz-
ing antibody response and on IFN-a (31, 38, 39). Most of
the C32/2 mice infected with 2 3 106 pfu died within
8–10 d after infection despite a quite normal antibody re-
sponse. VSV infects neuronal tissue and causes paralysis and
death after infection of the spinal cord and the brain. A ti-
tration of the infectious dose of VSV revealed an increased
susceptibility to VSV by at least a factor of 100–1,000 (Ta-
ble I) in complement-deficient mice. Whereas six of nine
C32/2 mice infected intravenously with 105 pfu died, only
one of six control animals died after infection with 107 pfu
VSV. High VSV titers were found in the brains of para-
lyzed mice (Table I), implying infection of the central ner-
vous system by VSV as cause of disease and death. In con-
trast, no increased susceptibility to VSV was observed after
infection of CR22/2 mice (not shown).
A number of factors may have contributed to this drastic
increase in susceptibility to disease (as a comparison, the
LD50 of antibody-deficient mMT mice is z103 pfu VSV;
reference 40) may be explained as follows: First, the ob-
served delay in the neutralizing IgM antibody response may
allow VSV to reach its target tissue, the brain, before a suf-
ficiently high neutralizing antibody titer is mounted. Sec-
ond, complement components may directly—or indirectly
via antibodies—inactivate VSV and reduce peripheral in-
fection. Third, opsonization with complement could lead
to a more efficient recruiting of the virus to secondary
lymphoid organs and therefore an enhanced clearance of
Table I. Susceptibility of C32/2 and Control Mice to Infection 
with VSV
Infectious dose
injected
Survival of animals
in each group*
VSV brain titers (log10)
(numbers of mice tested)‡
C32/2 Controls§ C32/2 Controls§
107 pfu 0/6 5/6 5.3 6 1.7 (6) 6.1 (1)
,1.7 (5)
105 pfu 3/9 6/6 6.3 6 2.7 (6) ,1.7 (6)
103 pfu 3/3 3/3 ,1.7 (3) ,1.7 (3)
*Results are shown as the number of surviving mice/total number of
mice tested. Mice that became visibly sick (hind leg paralysis) were
killed according to Swiss law for animal protection. Surviving mice
were followed up to 60 d.
‡Brain virus titers of paralyzed mice were assessed 8–10 d after VSV in-
fection and are given as mean 6 SD log10. VSV titers in brains of
healthy mice were below detection limit (,1.7).
§(C57BL/6 3 129Sv)F1 animals were used as controls.1169 Ochsenbein et al.
virus from the circulation. These possibilities are analyzed
in the following sections.
No Thymus-independent Activation of B Cells in C32/2
Mice. The observation that the early (day 2–6) TI IgM re-
sponses against VSV and Vacc VSV G were reduced
whereas the TD IgM response after infection with LCMV
was normal was unexpected, as earlier studies with nonrep-
licating model antigens had suggested that mainly TD anti-
body responses were enhanced by complement-mediated
stimulation of the B cell coreceptor complex (CR2–
CD19–TAPA-1) (5–8, 10).
Analysis of B cell responses in mice depleted of CD41 T
cells revealed that the IgM response was reduced in C32/2
by a factor of 250 compared with control mice on day 6 af-
ter infection with 2 3 106 pfu VSV i.v. (Fig. 2 B compared
with Fig. 1 A), i.e., in the absence of C3, the normally TI
antibody response was almost completely blocked. Neu-
tralizing IgG (distinguished from IgM by reduction with
0.1 M b-ME, an unequivocal means of destroying IgM;
reference 41) on day 8 after immunization was at least two
titer steps lower than total Ig, indicating that the antibodies
measured until day 8 largely represented neutralizing IgM.
The efficiency of the CD41 T cell depletion protocol was
verified by FACS™ analysis of the CD41 T cell counts in
the blood (not shown). In addition, no switch to IgG was
observed in mice treated with anti-CD41 antibodies, indi-
cating that depletion of T cell help in vivo was efficient
(Fig. 2, A–E). To assess the pathway of complement activa-
tion and the mechanisms by which complement contrib-
utes to Th cell–independent B cell activation, we analyzed
the early neutralizing IgM response to VSV in CD41 T
cell–depleted C42/2 (Fig. 2 C), CR22/2 (Fig. 2 D), and
CD192/2 mice (Fig. 2 E) and compared it to the antibody
response in equally treated control mice (Fig. 2 A). Similar
to C32/2 mice, the early neutralizing IgM antibody re-
sponse to VSV was delayed in C42/2 mice and depended
largely on T cell help. This indicated that early during VSV
infection, the complement cascade was probably activated
via the classical pathway. In contrast, mice deficient in the
CR1 and -2 (CR22/2, Fig. 2 D) or the coreceptor compo-
nent CD19 (Fig. 2 E) mounted early neutralizing IgM titers
that were independent of T cell help. Therefore, the effect
of complement on the early antibody response could not
be explained by the lack of stimulation via the B cell core-
ceptor complex. In an earlier study, complement inactiva-
tion using cobra venom factor (CVF) could not reveal an
influence of complement on the IgM responses against
VSV (42). However, although inactivation using CVF may
be efficient for serum complement components, it was
shown to be rather inefficient for locally produced comple-
ment components in secondary lymphoid organs (43).
To analyze whether the impaired TI antibody response
in C-deficient mice was unique to VSV or was a general
phenomenon, we studied antibody responses of C32/2 and
control mice after immunization with Vacc VSV G (Fig. 3,
A and B) or poliomyelitis virus (Fig. 3, C and D). IgM re-
sponses to both of these TI-2 antigens were also largely de-
pendent on T cell help in C32/2 mice.
Complement Recruits Viral Antigen to the Splenic Marginal
Zone. Because the TI activation of B cells was not depen-
dent on CR1 or -2, the effect may be mediated by CR3
(CD11b, CD18) or CR4 (CD11c, CD18) (44). These re-
ceptors are mainly expressed on macrophages. Immunohis-
tological analysis after immunization with VSV antigen
showed a high concentration of VSV antigen accumulated
in the splenic marginal zone in control (C57BL/6 3
129Sv)F1 mice (Fig. 4 C). In contrast, this local concentra-
tion was virtually absent in C32/2 mice (Fig. 4 D). The
staining of the marginal zone macrophages with MOMA-1
(specific for metallophilic macrophages of the marginal
zone; Fig. 4, A and B) and ERTR-9 (specific for marginal
zone macrophages; not shown) confirmed that C32/2 mice
possessed a normal marginal zone structure. Interestingly,
VSV titers in the spleen 6 h after infection with 2 3 108
pfu VSV were comparable in C32/2 and control mice (Ta-
ble II). This difference may be explained by the fact that
immunohistochemically, only high concentrations of anti-
gen can be stained. In contrast, under conditions where an-
tigen is distributed more diffusely in the spleen, as in C32/2
Figure 2. T cell dependence of VSV-specific IgM antibody responses.
Control (C57BL/6 3 129Sv)F1 (A), C32/2 (B), C42/2 (C), CR22/2
(D), and CD192/2 (E) were infected with 2 3 106 pfu VSV. Total VSV-
neutralizing Ig was assessed at the time points indicated. Mice were either
depleted of CD41 T cells (two 200-ml administrations of anti-CD4 anti-
body YTS191.1, on day 3 and day 1) or left untreated. Efficiency of
CD41 T cell depletion was checked by FACS™. Neutralizing IgG (cir-
cles) was assessed on day 8 (reduction with b-ME) and was always at least
two titer steps lower than total Ig, indicating that antibody titers up to day
8 represent IgM. One of three comparable experiments is shown.1170 Complement in Viral Infections
mice, no intensive immunohistological signal can be de-
tected. Thus, complement mainly influenced the specific
targeting of the antigen to marginal zone macrophages but
less influenced the general uptake of virus in the spleen.
Complement Augments the Protective Capacity of Neu-
tralizing Antibodies. The only slightly impaired anti-
body  response in C32/2 mice was in contrast to the mas-
sively increased mortality after infection with VSV. We
therefore tested the protective capacity of a panel of seven
monoclonal IgM and five monoclonal IgG VSV-specific
neutralizing antibodies after transfer into C32/2 or control
mice (45). The results obtained with the antibodies with
the highest and the lowest in vitro neutralization titers are
shown in Table II. Viral titers in the spleens of C32/2 and
control mice 6 h after infection with 2 3 108 pfu VSV
were similar, z6 log10, and comparable titers were also ob-
tained in peripheral organs (liver and kidney; data not
shown). Injection of neutralizing IgM or IgG antibodies
20–30 min before VSV infection reduced viral organ titers
in control mice by 100–1,000-fold but only reduced titers
in C32/2 mice z10-fold (Table II). The augmentation of
the neutralizing capacity of mAbs by complement was con-
firmed with the administration of pooled, complement-
inactivated polyclonal IgM of day 4 VSV immune mice 20–
30 min before infection with 2 3 108 pfu VSV (Table II).
In contrast, the neutralization of noncytopathic LCMV
with IgM or IgG mAbs seems to be largely independent of
complement in vivo (Table II). These results differ from
earlier in vitro observations that suggested a direct role of
complement in protection against LCMV (46).
In summary, the VSV-neutralizing antibodies are more
efficient in vivo in the presence of an intact complement
system.
Antiviral B Cell Memory Is Not Complement Dependent.
Complement has been shown to be involved in targeting
antigen to CD21 and CD35 on FDCs in GCs, where the
survival of GC B cells is dependent on the expression of
CRs (23, 24, 47). To assess antiviral B cell memory, C32/2,
C42/2, CR22/2, or CD192/2 mice were infected with
2 3 106 pfu VSV, and antibody titers were followed up to
150 d. C32/2, C42/2, and CR22/2 mice maintained IgG
antibody titers comparably to control mice (Fig. 5, A–C).
In contrast, CD192/2 mice lost memory antibody titers
within 90 d (Fig. 5 D), confirming earlier results (33). On
day 120 after the initial infection, the number of AFCs was
assessed in the bone marrow (Fig. 5 E) and spleen (Fig. 5
F). C32/2 and control mice had similar numbers of AFCs
in the bone marrow and spleen, a finding that correlated
with the observed antibody titers. The AFCs in C42/2 and
CR22/2 mice in the bone marrow were reduced by 80–
90% and in the spleen by z50% compared with the num-
ber of AFCs present in control mice. The AFCs in CD192/2
mice were reduced by .99.9% in the bone marrow and
the spleen, confirming earlier results analyzing B cell mem-
ory in CD192/2 mice (33). The reduced numbers of AFCs
in C42/2 and CR22/2 mice by a factor of 5 or 2 in spleen
or bone marrow, respectively, were still sufficient to main-
tain long-term antibody titers after immunization with
VSV. However, in CD192/2 mice, where AFCs are re-
duced by a factor of 100–1,000, neutralizing antibody titers
Figure 3. TD IgM antibody responses to recombinant vaccinia virus
and poliomyelitis virus. C32/2 and control mice (either depleted of
CD41 T cells or left untreated) were immunized with 2 3 106 pfu Vacc
VSV G (A and B), and neutralizing antibody titers were assessed every
other day. Neutralizing IgG (circles) was determined 8 d after immuniza-
tion and was always at least two titer steps lower than total Ig, indicating
that antibody titers until day 8 represent IgM. CD41 T cell–depleted and
untreated control (C) or C32/2 (D) mice were immunized with 500 ml of
inactivated polio vaccine (Salk), and polio virus (serotype II)-specific neu-
tralizing antibodies were assessed until day 8. No switch to IgG was ob-
served after single immunization with polio vaccine. The experiment was
repeated twice with comparable results.
Figure 4. Recruitment of viral antigen to the spleen. The spleens of
naive (C57BL/6 3 129Sv)F1 (A, control) and C32/2 (B) mice were stained
with MOMA-1 (specific for metallophilic macrophages of the marginal
zone). Control and C32/2 mice were immunized intraperitoneally with
viral antigen derived from disrupted VSV-infected BHK cells. 1 d later,
VSV antigen was stained on spleen sections as described in Materials and
Methods (original magnification: A and B, 125; C and D, 250). One of
two comparable experiments is shown.1171 Ochsenbein et al.
could not be maintained. B cell memory was also assessed
in C32/2 mice 150 d after infection with Vacc VSV G,
VSV G protein, and LCMV. Long-term antibody titers af-
ter these different immunization protocols were compara-
bly maintained in C32/2 and control mice (not shown).
Discussion
Complement may be involved in a viral infection in var-
ious ways (3), and its importance for host protection is doc-
umented here by the increased susceptibility of C32/2 mice
to a model infection with the cytopathic virus VSV. VSV
activates the complement cascade via the classical pathway,
i.e., antibodies initially activate the C1 convertase or, as de-
scribed for some retroviruses, the classical pathway is di-
rectly activated by virus-infected cells independent of anti-
bodies (48). Natural IgM antibodies to VSV are present in
the serum of antigen-inexperienced mice and can bind to
virus and activate the complement cascade (49, 50). Com-
plement may then directly augment the efficiency of anti-
bodies to neutralize VSV. Early in vitro studies had shown
that the active cleavage product C3b bound to VSV and
was incorporated into its surface and, thereby, may have
prevented infection of target cells (50). Also, a role of com-
plement has been demonstrated in in vitro studies with var-
ious viruses including LCMV and HIV (4, 51, 52), but in
Table II. Protective Capacity of Neutralizing Antibodies after Infection with VSV or LCMV in C32/2 and (C57BL/6 3 129Sv)F1 
Control Mice
Antibody* Class Dose‡
Antibody
titer§ Mouse
Virus titer
in the spleeni
D Fold increase
in virus titer
Infection with 2 3 108 pfu VSV i.v.:
–– – – C 3 2/2 6.0 6 0.1
,2
Control 5.8 6 0.1
M4C11H12 IgM 10 mg 150 C32/2 5.9 6 0.3
500
Control 3.2 6 0.6
H2F1C1 IgM 10 mg 6,600 C32/2 4.7 6 0.1
30
Control 3.2 6 0.2
C3C5B9 IgG1,k 10 mg 175 C32/2 6.2 6 0.7
80
Control 4.3 6 0.4
E5D9H5 IgG1,k 10 mg 14,580 C32/2 4.6 6 0.2
50
Control 2.9 6 0.7
Polyclonal IgM 500 ml 40,960 C32/2 4.4 6 0.1
20
Control 3.1 6 0.1
Infection with 200 pfu LCMV i.v.:
,2 –– – – C 3 2/2 6.6 6 0.4
Control 6.7 6 0.1
,2 H25 IgM 500 ml 20,480 C32/2 3.7 6 0.1
Control 3.9 6 0.7
Infection with 2 3 106 pfu LCMV i.v.: 
–– – – C 3 2/2 7.4 6 0.5
,2
Control 7.1 6 0.1
KL25 IgG 100 mgC 3 2/2 6.9 6 0.4
5
Control 6.2 6 0.1
*Generation of VSV-IND– and LCMV-WE–specific mAbs was described (45, 56). A panel of seven monoclonal IgM- and five monoclonal VSV-
IND–specific neutralizing antibodies was tested. Two representative examples of each class are shown. Pooled sera of day 3 and 4 VSV-IND–
immune mice were used as polyclonal IgM (complement was inactivated by incubation at 56°C for 30 min before transfer). LCMV-WE–specific
IgM antibodies were from LCMV-immune transgenic H25 mice (57). IgG1,k 5 IgG1 with kappa light chain.
‡All antibodies were injected intravenously 20–30 min before injection. The dose injected is given in micrograms for mAbs derived from hybrid-
omas in vitro and in microliters for pooled sera gained in vivo.
§Neutralizing antibody titer (see Materials and Methods) is indicated for hybridomas for 1 mg/ml mAb or for pooled serum.
iVirus titers in organs were determined by a plaque-forming assay as described in Materials and Methods. VSV titers were analyzed 6 h after infec-
tion, whereas LCMV titers were measured 48 h after infection with 2 3 106 pfu LCMV or 4 d after infection with 200 pfu LCMV, respectively.
Only titers in the spleen are shown. Viral titers in blood, kidney, and liver revealed similar differences between C32/2 and control mice. Titers are
given as mean 6 SD of three to four animals per group. The experiment was repeated twice.1172 Complement in Viral Infections
extension of earlier in vitro experiments (51), in this study
we could not detect a direct influence of complement on
the severity of LCMV infection in vivo.
A surprising effect of complement was found here on vi-
ruses that elicit an antibody response independently of T
cell help. Several viruses have been shown to be TI anti-
gens, e.g., influenza, polio, rabies virions, and others (53).
After infection with a cytopathic virus such as VSV, early
defense mechanisms are crucial to prevent infection of neu-
ronal tissue. Complement does not seem to directly influ-
ence early distribution of VSV, as C32/2 and control mice
have comparable titers of VSV in the spleen and in periph-
eral organs 6 h after infection. Nevertheless, complement-
coated virus is targeted more efficiently to CR-expressing
cells. This effect has been extensively analyzed and docu-
mented for CD21 and CD35 expressed on FDCs (23, 47),
suggesting an influence on antigen persistence in GCs that
may have an impact on long-term B cell memory. After in-
fection with VSV, LCMV, and different recombinant anti-
gens, we did not observe any impairment in B cell memory
in mice deficient in complement components or CRs, al-
though AFCs in C42/2 and CR22/2 mice were reduced
by a factor of 2–5. The binding of antigen IgG complexes
on FDC seems to be sufficient to maintain long-term B cell
memory after a viral infection (47). The observations that
C32/2, C42/2, and CR22/2 mice maintained B cell mem-
ory, whereas CD192/2 mice had a drastic reduction in IgG
antibody titers and AFCs 90–150 d after infection remains
unexplained. So far, it was assumed that CD19 signaled
solely after binding of C3d to CR2, as no specific ligand
for CD19 is known (5, 33). However, the different pheno-
type of CD192/2 and CR22/2 mice is best explained by an
intrinsic role of CD19 in BCR signaling. Alternatively,
there might be a ligand for CD19 that is independent of
the CR. In a different set of experiments, B cell memory to
another infectious virus, human herpes simplex type 1, that
replicates only to a very limited extent in mice, particularly
when injected subcutaneously (a condition probably more
comparable to immunization with UV-inactivated VSV),
was found to be classical pathway and CD21 dependent
(53a). Thus, in addition to antigen dose and replication ca-
pacity, the antigenic structure and the route of infection
might be important determinants of whether and to what
extent complement is required for humoral responses.
Early on during a viral infection, a sufficient antigen
concentration on CR3– and -4–expressing macrophages in
the splenic marginal zone seems to be crucial to elicit an
early, TI B cell response. Marginal zone macrophages have
been shown to be important for the induction of TI-2 an-
tibody responses to nonreplicating model antigens (54).
This mechanism causes a very efficient early IgM response
necessary for survival of the infection. Any delay in the
early neutralizing antibody response may allow the virus to
reach neuronal tissue before an efficient neutralizing anti-
body response is mounted.
Our results suggested that lowering the threshold of B
cell activation by binding to the B cell coreceptor (CR2,
CD19, TAPA-1) does not seem to play a major role after
infection with live viral antigens. However, signaling via
the B cell coreceptor enhanced the IgG response when
nonreplicating antigens were used. This difference may be
explained by nonspecific inflammatory reactions and cy-
tokine secretion plus prolonged antigen persistence during
infections with live virus that may compensate for the lack
of costimulation via CR2/CD19 (55).
In conclusion, during a viral infection, complement is an
important link to adaptive immunity: it helps to recruit an-
tigen to marginal zone macrophages and stimulate B cells
of the marginal zone and thereby enhances specific TI anti-
body responses. Thus, TI IgM antibody responses are com-
plement dependent.
Figure 5. Long-term antibody and B cell memory in complement-
deficient mice. C32/2 (A), C42/2 (B), CR22/2 (C), and CD192/2 (D)
mice were immunized with 2 3 106 pfu VSV, and long-term antibody ti-
ters were compared with controls. Three of six C32/2 and two of five
C42/2 animals died between day 8 and 12 after immunization. Antibody
titers in surviving and dying mice were comparable until day 8. Antibody
titers in surviving animals were followed up to day 120. 120 d after infec-
tion, VSV-specific AFCs in the spleen (F) and bone marrow (E) were as-
sessed in an enzyme-linked immunospot assay. Results are given as mean 6
SD of three mice per group. Experiments were repeated twice with com-
parable results.1173 Ochsenbein et al.
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